Africa's Health Data: A New Colonial Extractivism?

Zimbabwe recently withdrew from a $367 million US health funding agreement, citing objections to broad American access to sensitive health data. The proposed five-year program, intended for HIV/AIDS, tuberculosis, malaria, and epidemic preparedness, demanded extensive sharing of national health intelligence, including epidemiological data and pathogen samples.

Zambia and Kenya are also expressing concerns over similar large-scale US health partnerships. Zambia faces demands for domestic co-financing and broad data access, while Kenya's High Court suspended a $2.5 billion agreement due to data protection issues. These situations underscore a growing pattern of US bilateral health strategies across Africa.

Critics describe this trend as 'biomedical extractivism,' a practice that reinforces Western dominance by exploiting research and colonial thinking. African countries risk becoming mere suppliers of biological information, while the lucrative benefits of intellectual property and pharmaceutical profits remain concentrated in wealthier nations.

These concerns echo historical instances of imperial power intertwined with medicine in Africa. Modern medical ethics debates, including past controversial drug trials by Western pharmaceutical companies, further shape current skepticism regarding these agreements.

The core issue is not data sharing itself, but the equitable access to resulting technologies. African nations must balance vital health programs with data sovereignty, advocating for collective negotiation through bodies like the African Union to ensure fair partnerships and prevent new forms of imperial control.